About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Diagnostic Value of eVOG | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT05776511

Diagnostic Value of eVOG

Eye movement is a complex neurological function controlled by many structures located in the central nervous system. The eyeball is mobile within the orbit and its movements are carried out using 6 mu...

Lead sponsor: Centre Hospitalier Universitaire de Nice•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Mikael COHEN

CONTACT

33492038252 [email protected]

Cassandre LANDES CHATEAU

CONTACT

33492034126 [email protected]

Sponsors

Lead Sponsor

Centre Hospitalier Universitaire de Nice

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients referred to our tertiary center for a diagnostic workup of white matter hypersignals
•Absence of oculomotor disorders on conventional clinical examination
•Age \> 18 years
•The controls can be recruited from the accompanying persons of the patients selected for the study, from the staff of the CHU of Nice or from the entourage of the investigating team;
•Absence of known oculomotor disorders by the control
•Age \> 18 years

Exclusion Criteria

•Presence of a neurological, ophthalmological or general pathology that may interfere with the performance of digital video oculography

Related studies

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis

RECRUITINGPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 · Relapsing Multiple Sclerosis

Nomad P-KAFO Study

NCT05644522 · Cerebrovascular Accident, Post-polio Syndrome, and more

RECRUITINGPhase 2

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399 · Multiple Sclerosis

RECRUITINGPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724 · Relapsing Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 17, 2024Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment150

Start dateApr 2023

Last updatedApr 17, 2024

Condition

Multiple Sclerosis Radiologically Isolated Syndrome White Matter Lesions

Locations shown

Nice University Hospital

Nice

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions